Training in HIV/AIDS Prevention and Treatment Research in Botswana

博茨瓦纳艾滋病毒/艾滋病预防和治疗研究培训

• 批准号: 9975952
• 负责人: SHAHIN LOCKMAN
• 金额: $ 30.06万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9975952
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Advisory Committees; Africa; Anti-Retroviral Agents; Botswana; Country; Developing Countries; Doctor of Philosophy; Educational workshop; Environment; Epidemic; Faculty; Funding; Goals; Government; HIV; Health; High Prevalence; Individual; Institutes; Institution; Journals; Modernization; Monitor; Patients; Performance; Pharmacotherapy; Positioning Attribute; Postdoctoral Fellow; Prevention; Prevention Research; Public Health Schools; Publications; Research; Research Activity; Research Personnel; Research Training; Safety; Site; Teacher Professional Development; Testing; Training; Training Programs; Treatment outcome; Universities; base; experience; faculty mentor; low and middle-income countries; pre-doctoral; programs; success; training opportunity; treatment program; treatment research

PROJECT ABSTRACT The focus for this proposal is research training for people from Botswana in relation to the various uses of ART for prevention and treatment in the modern era of the HIV epidemic. Recent advancements in coverage strategies and antiretroviral combinations within the Botswana national ART program offer a unique environment for use of modern HIV treatment, safety, and prevention research for the developing world, with a host of research opportunities for training researchers in Botswana, to match current research activities of the faculty mentors and key partners at the Botswana site. The in-country institution for this proposal is the Harvard T.H. Chan School of Public Health, and our LMIC partner for training is the Botswana Harvard AIDS Institute Partnership (BHP), a limited liability nonprofit corporation (LLC) with the Ministry of Health (MOH) in Botswana. BHP is the largest HIV/AIDS research organization in Botswana, and one of the largest in Africa. The long-term goals and objectives of this training program are to train research leaders for BHP, the University of Botswana, and the MOH. Botswana currently has one of the highest prevalence rates of HIV in the world (22%), but has also had the highest rate of antiretroviral drug treatment (ART) for patients with HIV (about 90%) in Africa. The government of Botswana currently operates the most advanced HIV treatment program in Africa, using a universal test-and-treat strategy. The training faculty at Harvard and BHP will focus on how “modern” ART impacts treatment outcomes, safety, and prevention research. HIV-related courses, seminars, and workshops are available for trainees. We have requested funds for 2 predoctoral and 3 postdoctoral positions each year. We estimate that we will train about 18 trainees over 5 years, allowing for multiple years for each PhD candidate and some postdoctoral fellows, and assuming several short-term trainees could fill a single annual training slot. Stipends will be based on current degrees and research experience; thus an MD on an MS or PhD program would be eligible for a postdoctoral-level stipend. Each trainee will have a principal advisor and a faculty advisory committee. Selection of trainees is based on previous academic performance, references, experience, and assurance that the candidates will return to participate in HIV research in Botswana. The quality of the program will be monitored by a Training Advisory Committee composed of experts from the US and from developing countries. The success of the training program will be judged by the relative increase in senior research positions at BHP, UB, and MOH that are individuals who were trained by this program after the second and fourth years. Success will also be judged by the implementation of successful prevention research programs that involve trainees, numbers of trainee publications in high-impact journals, and number of staff positions filled by former trainees at the BHP and the Ministry of Health.

项目摘要 这项建议的重点是对博茨瓦纳人进行有关抗逆转录病毒疗法各种用途的研究培训 在艾滋病流行的现代，覆盖面的最新进展 博茨瓦纳国家抗逆转录病毒疗法计划中的抗逆转录病毒策略和组合提供了一个独特的 为发展中国家提供现代艾滋病毒治疗、安全和预防研究的环境， 为培训博茨瓦纳的研究人员提供大量研究机会，以配合联合国目前的研究活动， 教师导师和博茨瓦纳网站的主要合作伙伴。本提案的国内机构是 哈佛T. H.我们的LMIC培训合作伙伴是博茨瓦纳哈佛艾滋病研究所 研究所伙伴关系（BHP），一家有限责任的非营利公司（LLC）与卫生部（MOH）， 波札那. BHP是博茨瓦纳最大的艾滋病毒/艾滋病研究组织，也是非洲最大的研究组织之一。 该培训计划的长期目标和目的是为必和必拓培训研究领导者， 博茨瓦纳大学和卫生部。博茨瓦纳目前是艾滋病毒流行率最高的国家之一， 艾滋病患者的抗逆转录病毒药物治疗（ART）率也是最高的 （约90%）在非洲。博茨瓦纳政府目前正在进行最先进的艾滋病毒治疗 在非洲的一个项目，使用一种普遍的测试和治疗策略。哈佛和必和必拓的培训教师将专注于 “现代”ART如何影响治疗结果，安全性和预防研究。 为学员提供与艾滋病毒有关的课程、研讨会和讲习班。我们已经申请了2笔资金 每年有3个博士后岗位。我们估计，我们将培训约18名学员， 年，允许每个博士候选人和一些博士后研究员多年，并假设 几名短期受训人员可以填补一个年度培训名额。津贴将根据目前的程度 和研究经验;因此，在MS或博士课程的MD将有资格获得博士后水平 津贴。每个学员将有一个主要顾问和一个教师咨询委员会。学员的选拔是 根据以前的学术表现，参考，经验，并保证候选人将 返回博茨瓦纳参加艾滋病毒研究。该计划的质量将由培训监督 咨询委员会由来自美国和发展中国家的专家组成。的成功 培训计划将根据必和必拓、UB和卫生部高级研究职位的相对增加来判断， 是在第二年和第四年后接受该计划培训的个人。成功也将是 根据成功实施的有受训人员参与的预防研究方案来判断， 受训人员在影响力大的期刊上发表文章的数量，以及前受训人员在必和必拓担任的工作人员职位的数量 和卫生部。